Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cephalon's Buchi Steps In To Fill Baldino's Big Shoes

This article was originally published in The Pink Sheet Daily

Executive Summary

Founder and CEO Frank Baldino is taking a temporary medical leave of absence, but the company says he will be back before the end of the year.

You may also be interested in...



Cephalon Makes A $130 Mil. Bet On Australian Mesoblast's Stem Cell Technology

Cephalon is making a significant bet on an Australian biotech's adult stem cell technology, taking it forward in multiple indications, including some fields where it isn't currently active, but which its executives say it can get up to speed on quickly. The deal is the specialty pharma company's fourth in biologics since it announced nearly two years ago that expanding into biologics would be a priority

Cephalon Makes A $130 Mil. Bet On Mesoblast's Stem Cell Technology

The U.S. specialty pharma continues its multi-year effort to expand into biologics by licensing in the Australian biotech's adult stem cell technology for cardiovascular, oncology, and neurodegenerative indications.

Cephalon Makes A $130 Mil. Bet On Mesoblast's Stem Cell Technology

The U.S. specialty pharma continues its multi-year effort to expand into biologics by licensing in the Australian biotech's adult stem cell technology for cardiovascular, oncology, and neurodegenerative indications.

Related Content

Topics

UsernamePublicRestriction

Register

LL1135972

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel